Infinium Pharmachem Limited (NSE:INFINIUM)

Market Cap	3.20B -20.2%
Revenue (ttm)	1.90B +21.8%
Net Income	121.50M +49.2%
EPS	7.80 +39.3%
Shares Out	15.58M
PE Ratio	26.29
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,500
Open	205.05
Previous Close	205.05
Day's Range	205.00 - 211.00
52-Week Range	189.40 - 297.00
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Infinium Pharmachem

Infinium Pharmachem Limited engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. The company provides iodine based molecules/APIs/iodination reaction based bulk drugs. It also offers potassium iodide and iodate, sodium iodide, iodine, povidone iodine, pralidoxime iodide, thymol iodide, and iodoform products. In addition, the company provides contract research and manufacturing services to pharmaceutical and biotech companies for iodine based APIs and inte...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2003
• Employees: 144
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INFINIUM

Financial Performance

In fiscal year 2026, Infinium Pharmachem's revenue was 1.90 billion, an increase of 21.79% compared to the previous year's 1.56 billion. Earnings were 121.50 million, an increase of 49.17%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error